Literature DB >> 20536413

Targeting IL-23 in human diseases.

Mario M D'Elios1, Gianfranco Del Prete, Amedeo Amedei.   

Abstract

IMPORTANCE OF THE FIELD: IL-23 is one of the most intriguing cytokine for its many immunological functions, which are the basis of its important role in host defense but also of its possible contribution to the pathogenesis of several diseases. AREAS COVERED IN THIS REVIEW: The literature and patents about IL-23 pathway and their targeting in therapeutic potential applications. Findings published within the last 5 years receive particular attention. WHAT THE READER WILL GAIN: An overview of the emerging role of IL-23 in physiological and pathological conditions and a review of the different approaches (IL-23 pathway-based) currently used for autoimmune diseases and cancer therapies and the results obtained both in preclinical models and in clinical trials. TAKE HOME MESSAGE: Inhibition/targeting of IL-23 may be a good and novel therapeutic strategy, especially in the treatment of diseases like psoriasis, for which current treatments show more pronounced side effects than those of IL-23-blocking and employed as part of specific patient-tailored therapies in inflammatory bowel diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536413     DOI: 10.1517/14728222.2010.497143

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  8 in total

1.  Linkage of gut microbiome with cognition in hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Jason M Ridlon; Phillip B Hylemon; Leroy R Thacker; Douglas M Heuman; Sean Smith; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-09-22       Impact factor: 4.052

2.  Kynurenic acid downregulates IL-17/1L-23 axis in vitro.

Authors:  Sanam Salimi Elizei; Malihe-Sadat Poormasjedi-Meibod; Xia Wang; Maryam Kheirandish; Aziz Ghahary
Journal:  Mol Cell Biochem       Date:  2017-03-11       Impact factor: 3.396

3.  Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.

Authors:  Jasmohan S Bajaj; Phillip B Hylemon; Jason M Ridlon; Douglas M Heuman; Kalyani Daita; Melanie B White; Pamela Monteith; Nicole A Noble; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-07-19       Impact factor: 4.052

4.  Functional polymorphisms in interleukin-23 receptor and susceptibility to coronary artery disease.

Authors:  Meiyan Zhang; Zhen-Rong Cai; Bili Zhang; Xinmeng Cai; Wei Li; Zhifu Guo; Lan Ma
Journal:  DNA Cell Biol       Date:  2014-12       Impact factor: 3.311

Review 5.  Immune Signatures in Patients with Psoriasis Vulgaris of Blood-Heat Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Xin Li; Qing-Qing Xiao; Fu-Lun Li; Rong Xu; Bin Fan; Min-Feng Wu; Min Zhou; Su Li; Jie Chen; Shi-Guang Peng; Bin Li
Journal:  Evid Based Complement Alternat Med       Date:  2016-05-04       Impact factor: 2.629

Review 6.  Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Qingdong Guan; Jiguo Zhang
Journal:  Mediators Inflamm       Date:  2017-03-21       Impact factor: 4.711

Review 7.  Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.

Authors:  Sasha R Fehily; Aysha H Al-Ani; Jonathan Abdelmalak; Clarissa Rentch; Eva Zhang; Justin T Denholm; Douglas Johnson; Siew C Ng; Vishal Sharma; David T Rubin; Peter R Gibson; Britt Christensen
Journal:  Aliment Pharmacol Ther       Date:  2022-05-20       Impact factor: 9.524

8.  Platelets and inflammatory markers in patients with gastric cancer.

Authors:  Joanna Matowicka-Karna; Zbigniew Kamocki; Beata Polińska; Joanna Osada; Halina Kemona
Journal:  Clin Dev Immunol       Date:  2013-03-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.